miR-218-5p and doxorubicin combination enhances anticancer activity in breast cancer cells through Parkin-dependent mitophagy inhibition
Abstract Breast Cancer (BC) is one of the most common tumours, and is known for its ability to develop resistance to chemotherapeutic treatments. Autophagy has been linked to chemotherapeutic response in several types of cancer, highlighting its contribution to this process. However, the role of mit...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-03-01
|
| Series: | Cell Death Discovery |
| Online Access: | https://doi.org/10.1038/s41420-024-01914-7 |
| _version_ | 1797247450637926400 |
|---|---|
| author | Francesco Davide Naso Krenare Bruqi Valeria Manzini Valerio Chiurchiù Mara D’Onofrio Ivan Arisi Flavie Strappazzon |
| author_facet | Francesco Davide Naso Krenare Bruqi Valeria Manzini Valerio Chiurchiù Mara D’Onofrio Ivan Arisi Flavie Strappazzon |
| author_sort | Francesco Davide Naso |
| collection | DOAJ |
| description | Abstract Breast Cancer (BC) is one of the most common tumours, and is known for its ability to develop resistance to chemotherapeutic treatments. Autophagy has been linked to chemotherapeutic response in several types of cancer, highlighting its contribution to this process. However, the role of mitophagy, a selective form of autophagy responsible for damaged mitochondria degradation, in the response to therapies in BC is still unclear. In order to address this point, we analysed the role of mitophagy in the treatment of the most common anticancer drug, doxorubicin (DXR), in different models of BC, such as a luminal A subtype-BC cell line MCF7 cells, cultured in 2-Dimension (2D) or in 3-Dimension (3D), and the triple negative BC (TNBC) cell line MDA-MB-231. Through a microarray analysis, we identified a relationship between mitophagy gene expressions related to the canonical PINK1/Parkin-mediated pathway and DXR treatment in BC cells. Afterwards, we demonstrated that the PINK1/Parkin-dependent mitophagy is indeed induced following DXR treatment and that exogenous expression of a small non-coding RNA, the miRNA-218-5p, known to target mRNA of Parkin, was sufficient to inhibit the DXR-mediated mitophagy in MCF7 and in MDA-MB-231 cells, thereby increasing their sensitivity to DXR. Considering the current challenges involved in BC refractory to treatment, our work could provide a promising approach to prevent tumour resistance and recurrence, potentially leading to the development of an innovative approach to combine mitophagy inhibition and chemotherapy. |
| first_indexed | 2024-04-24T19:58:53Z |
| format | Article |
| id | doaj.art-18b95df482b34b7490e2fdf2c2275611 |
| institution | Directory Open Access Journal |
| issn | 2058-7716 |
| language | English |
| last_indexed | 2024-04-24T19:58:53Z |
| publishDate | 2024-03-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Cell Death Discovery |
| spelling | doaj.art-18b95df482b34b7490e2fdf2c22756112024-03-24T12:10:30ZengNature Publishing GroupCell Death Discovery2058-77162024-03-0110111110.1038/s41420-024-01914-7miR-218-5p and doxorubicin combination enhances anticancer activity in breast cancer cells through Parkin-dependent mitophagy inhibitionFrancesco Davide Naso0Krenare Bruqi1Valeria Manzini2Valerio Chiurchiù3Mara D’Onofrio4Ivan Arisi5Flavie Strappazzon6IRCCS Santa Lucia FoundationIRCCS Santa Lucia FoundationEuropean Brain Research Institute (EBRI) “Rita Levi-Montalcini”Institute of Translational Pharmacology, CNREuropean Brain Research Institute (EBRI) “Rita Levi-Montalcini”European Brain Research Institute (EBRI) “Rita Levi-Montalcini”IRCCS Santa Lucia FoundationAbstract Breast Cancer (BC) is one of the most common tumours, and is known for its ability to develop resistance to chemotherapeutic treatments. Autophagy has been linked to chemotherapeutic response in several types of cancer, highlighting its contribution to this process. However, the role of mitophagy, a selective form of autophagy responsible for damaged mitochondria degradation, in the response to therapies in BC is still unclear. In order to address this point, we analysed the role of mitophagy in the treatment of the most common anticancer drug, doxorubicin (DXR), in different models of BC, such as a luminal A subtype-BC cell line MCF7 cells, cultured in 2-Dimension (2D) or in 3-Dimension (3D), and the triple negative BC (TNBC) cell line MDA-MB-231. Through a microarray analysis, we identified a relationship between mitophagy gene expressions related to the canonical PINK1/Parkin-mediated pathway and DXR treatment in BC cells. Afterwards, we demonstrated that the PINK1/Parkin-dependent mitophagy is indeed induced following DXR treatment and that exogenous expression of a small non-coding RNA, the miRNA-218-5p, known to target mRNA of Parkin, was sufficient to inhibit the DXR-mediated mitophagy in MCF7 and in MDA-MB-231 cells, thereby increasing their sensitivity to DXR. Considering the current challenges involved in BC refractory to treatment, our work could provide a promising approach to prevent tumour resistance and recurrence, potentially leading to the development of an innovative approach to combine mitophagy inhibition and chemotherapy.https://doi.org/10.1038/s41420-024-01914-7 |
| spellingShingle | Francesco Davide Naso Krenare Bruqi Valeria Manzini Valerio Chiurchiù Mara D’Onofrio Ivan Arisi Flavie Strappazzon miR-218-5p and doxorubicin combination enhances anticancer activity in breast cancer cells through Parkin-dependent mitophagy inhibition Cell Death Discovery |
| title | miR-218-5p and doxorubicin combination enhances anticancer activity in breast cancer cells through Parkin-dependent mitophagy inhibition |
| title_full | miR-218-5p and doxorubicin combination enhances anticancer activity in breast cancer cells through Parkin-dependent mitophagy inhibition |
| title_fullStr | miR-218-5p and doxorubicin combination enhances anticancer activity in breast cancer cells through Parkin-dependent mitophagy inhibition |
| title_full_unstemmed | miR-218-5p and doxorubicin combination enhances anticancer activity in breast cancer cells through Parkin-dependent mitophagy inhibition |
| title_short | miR-218-5p and doxorubicin combination enhances anticancer activity in breast cancer cells through Parkin-dependent mitophagy inhibition |
| title_sort | mir 218 5p and doxorubicin combination enhances anticancer activity in breast cancer cells through parkin dependent mitophagy inhibition |
| url | https://doi.org/10.1038/s41420-024-01914-7 |
| work_keys_str_mv | AT francescodavidenaso mir2185panddoxorubicincombinationenhancesanticanceractivityinbreastcancercellsthroughparkindependentmitophagyinhibition AT krenarebruqi mir2185panddoxorubicincombinationenhancesanticanceractivityinbreastcancercellsthroughparkindependentmitophagyinhibition AT valeriamanzini mir2185panddoxorubicincombinationenhancesanticanceractivityinbreastcancercellsthroughparkindependentmitophagyinhibition AT valeriochiurchiu mir2185panddoxorubicincombinationenhancesanticanceractivityinbreastcancercellsthroughparkindependentmitophagyinhibition AT maradonofrio mir2185panddoxorubicincombinationenhancesanticanceractivityinbreastcancercellsthroughparkindependentmitophagyinhibition AT ivanarisi mir2185panddoxorubicincombinationenhancesanticanceractivityinbreastcancercellsthroughparkindependentmitophagyinhibition AT flaviestrappazzon mir2185panddoxorubicincombinationenhancesanticanceractivityinbreastcancercellsthroughparkindependentmitophagyinhibition |